■2021.6.4.

Top-line results from Phase 1/2a clinical study of STNM01 as a second-line therapy for unresectable pancreatic cancer were presented by Dr. Tsuchiya at American Society of Clinical Oncology (ASCO) annual meeting 2021.
Title: A phase I/IIa trial of the RNA oligonucleotide STNM01 by EUS-FNI to investigate the safety and efficacy in patients with first-line refractory, unresectable pancreatic cancer.
https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.4120

■2018.4.26.

Nishimura M, et al. Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival in patients with unresectable pancreatic cancerGastrointest Endosc. 87:1126-1131, 2018.
https://www.ncbi.nlm.nih.gov/pubmed/29122598

■2018.3.22.

Phase 1/2a IIT program for unresectable pancreatic cancer was adopted by AMED innovative research program.
https://www.amed.go.jp/koubo/05/01/0501C_00003.html